Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Duke university HCQ-AZI, 2020
 
NCT04335552
RCThydroxychloroquine plus macrolidesstandard of careCOVID 19 hospitalizedNA
-/- inconclusive
    Arshad (HCQ AZ), 2020 OBShydroxychloroquine plus macrolidescontrolCOVID 19 hospitalizedcritical
    783/409 suggested
    • suggested 71 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
    Davido, 2020
     
    NCT04453501
    OBShydroxychloroquine plus macrolidescontrolCOVID 19 hospitalizedcritical
    52/40 suggested
    • suggested 55 % decrease in death or transfer to ICU but with a very low degree of certainty due to critical risk of bias
    Lagier, 2020 OBShydroxychloroquine plus macrolidescontrolCOVID 19 hospitalizedcritical
    3119/618 suggested
    • suggested 51 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
    • suggested 70 % decrease in clinical deterioration but with a very low degree of certainty due to critical risk of bias
    • suggested 62 % decrease in hospitalization but with a very low degree of certainty due to critical risk of bias
    Rosenberg, 2020 OBShydroxychloroquine plus macrolidescontrolCOVID 19 hospitalizedserious
    -/- safety concern
    • safety concern with statistically significant 1.1-fold increase in cardiac arrest
    • statistically significant 1.2-fold increase in arrhythmia but with a low degree of certainty due to high risk of bias
    Sbidian (HCQ plus AZI), 2020 OBShydroxychloroquine plus macrolidescontrolCOVID 19 hospitalizedcritical
    227/3792 inconclusive

      COVID 19 all comers meta-analysis

      Magagnoli (HC AZ), 2020 OBShydroxychloroquine plus macrolidescontrolCOVID 19 all comersserious
      113/158 inconclusive

        COVID-19 mild to moderate meta-analysis

        Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020
         
        NCT04322123
        RCThydroxychloroquine plus macrolidesstandard of careCOVID-19 mild to moderatesome concern
        217/227 safety concern
        • inconclusive 1 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
        • statistically significant 8.8-fold increase in long QT with a moderate degree of certainty due to some concern in risk of bias

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).